Detalhe da pesquisa
1.
Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma.
Nat Nanotechnol
; 18(2): 184-192, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702954
2.
Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors.
bioRxiv
; 2023 Aug 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37577538
3.
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Cancer Cell
; 40(11): 1358-1373.e8, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36379208
4.
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
Nat Cancer
; 1(5): 493-506, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33409501
5.
Author Correction: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma.
Nat Nanotechnol
; 18(4): 419, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36914884
6.
Author Correction: Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma.
Nat Nanotechnol
; 18(9): 1116, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37563269